Abstract
Novel therapies are needed to address the vascular endothelial cell (EC) barrier disruption that occurs in inflammatory diseases such as acute lung injury (ALI). We previously demonstrated the potent barrier-enhancing effects of both sphingosine 1-phosphate (S1P) and the structurally similar compound FTY720 [2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] in inflammatory lung injury. In this study, we examined the therapeutic potential of several novel FTY720 analogs to reduce vascular leak. Similar to S1P and FTY720, the (R)- and (S)-enantiomers of FTY720 phosphonate and enephosphonate analogs produce sustained EC barrier enhancement in vitro, as seen by increases in transendothelial electrical resistance (TER). In contrast, the (R)- and (S)-enantiomers of FTY720-regioisomeric analogs disrupt EC barrier integrity in a dose-dependent manner. Barrier-enhancing FTY720 analogs demonstrate a wider protective concentration range in vitro (1–50 μM) and greater potency than either S1P or FTY720. In contrast to FTY720-induced EC barrier enhancement, S1P and the FTY720 analogs dramatically increase TER within minutes in association with cortical actin ring formation. Unlike S1P, these FTY720 analogs exhibit differential phosphorylation effects without altering the intracellular calcium level. Inhibitor studies indicate that barrier enhancement by these analogs involves signaling via Gi-coupled receptors, tyrosine kinases, and lipid rafts. Consistent with these in vitro responses, the (S)-phosphonate analog of FTY720 significantly reduces multiple indices of alveolar and vascular permeability in a lipopolysaccharide-mediated murine model of ALI (without significant alterations in leukocyte counts). These results demonstrate the capacity for FTY720 analogs to significantly decrease pulmonary vascular leakage and inflammation in vitro and in vivo.
- ALI, acute lung injury
- BAL, bronchoalveolar lavage
- EC, endothelial cell
- HPAEC, human pulmonary artery endothelial cells
- LPS, lipopolysaccharide
- MβCD-cyclodextrin, MβCD-cyclodextrin
- MPO, myeloperoxidase
- MLC, myosin light chain
- PTX, pertussis toxin
- S1P, sphingosine 1-phosphate
- S1P1R, S1P1 receptor
- S1P3R, S1P3 receptor
- TER, transendothelial electrical resistance
- ERK, extracellular signal-regulated kinase
- WBC, white blood cells
- FTY720 (FTY), 2-amino-2-(2-[4-octylphenyl]ethyl)-13-propanediol
- 1R, (R)-FTY720 phosphonate
- 2R, (R)-FTY720 enephosphonate
- 3R, (R)-FTY720 regioisomer
- 1S, (S)-FTY720 phosphonate
- 2S, (S)-FTY720 enephosphonate
- 3S, (S)-FTY720 regioisomer
- FITC, fluorescein isothiocyanate
- PBS, phosphate-buffered saline.
Footnotes
-
This work was supported in part by the National Institutes of Health National Heart, Lung, and Blood Institute [Grant P01-HL58064, R01-HL68071, R01-HL79396, R01-HL88144] (to J.G.N.G., V.N., and S.M.D.); and the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [R01-DK07496602] (to M.R.).
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
ABBREVIATIONS:
- Received March 12, 2009.
- Accepted July 9, 2009.
- © 2009 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|